Radwan, Amal Fathy, Samya Hassan Okasha, Mona Abd Elmonem Hegazy, and Nagwa Ramadan Ahmed. "PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR- GAMMA GENETIC POLYMORPHISM AND NONALCOHOLIC STEATOHEPATITIS, CAN IT PREDICT DISEASE PROGRESSION!" International Journal of Advanced Research 4, no. 4 (2016): 1419-1429.ppar_article.pdf
El-Zanaty, Taher, Mona Hegazy, Heba Sedrak, and mervat naguib. "VARICEAL INDEX: SCORING SYSTEM FOR PREDICTION OF ESOPHAGEAL VARICES USING NON-INVASIVE PARAMETERS." International Journal of Current Research 8, no. 10 (2016): 40626-40629.variceal_index_article.pdf
hegazy, Mona Abd-Elmonem, Nehad Mohamed Tawfik, and Hoda Abd-Elstar Elrawei. "Liver injury and Khat leaves, a common toxic effect." Euroaisan J Hepato-Gastroenterology 2, no. 2 (2012): 70-75.khat_and_liver_reprint.pdf
Gohar, Nadida A., Dina F. Elgayar, Samar H. Aboulsoud, and Mona A. Hegazy. "Association of the Leu72Met polymorphism of the ghrelin." Comparative Clinical Pathology 21, no. 6 (2012): 1493-1499.ghrelin_article.pdf
hegazy, Mona Abd-Elmonem, Mohamed Sherif Mogawer, Heba Mahomud Ebrahim, Laila Ahmed Rashed, and Abeer Mostafa Elsayed. "Serum IGF-1, HOMA-IR and Estimated Glomerular Filtration Rate in Obese Patients with Different Stages of Hepatic Steatosis." EC GASTROENTEROLOGY AND DIGESTIVE SYSTEM 1, no. 5 (2017): 169-176. AbstractWebsite

Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver injury in many countries
around the world. The histological changes range over a wide spectrum, extending from simple steatosis, which is generally progressive,
to non alcoholic steatohepatitis (NASH) which may progress to liver fibrosis, liver cirrhosis, liver cell failure, and sometimes even
hepatocellular carcinoma. Liver biopsy is recommended as a gold standard method for the diagnosis and staging of steatosis and
fibrosis in patients with NAFLD. low IGF-I level are a consequence of the presence of both NASH/advanced fibrosis in adult patients
proved by liver biopsy which is a features of abdominal obesity and insulin resistance (HOMA-IR) and all contribute to the reduced
Objectives: Assessing the link between HOMA-IR, IGF-I level and eGFR in obese patient with different grades of severity of hepatic
steatosis proved by liver biopsy.
Methods: 54 overweight and obese patients preliminary diagnosed to have NAFLD by liver ultrasound ± elevated liver enzymes and
documented by liver biopsy, and 20 age , and sex matched normal Body mass index (BMI), healthy participants as a control group, had
been recruited in the current study. Diabetic patients and patients with elevated serum creatinine were excluded from the study. The
patients subjected to full medical history, anthropometric measurement, biochemical studies (liver enzymes, HCV antibody, HBVs
antigen, total lipid profile, serum creatinine, estimated glomerular filtration rate “eGFR”, fasting blood sugar, fasting insulin level to
calculate Homeostatic model assessment of insulin resistance “HOMA-IR”, and IGF-I). Abdominal ultrasound (US), and liver biopsy
for histological examination and NAS score to identify NASH patients, were conducted for each participant. According to NAS score,
patients were divided into 3 subgroups; NASH, border-line NASH, and non-NASH (simple steatosis). Healthy control participants
were not scheduled for liver biopsy for ethical consideration.
Results: According to the biopsy results; 7 patients had simple steatosis “not NASH”, 26 patients; border line NASH, and 21 patients
had NASH. BMI, and waist circumference were significantly higher in patients than control participant” p < 0.001”, and the highest
measurements were in NASH patients. ALT, GGT were significantly higher in NAFLD patients in general and in NASH patient subgroup.
HOMA-IR reached 3.57 ± 1.57 compared to 1.87 ± 0.43 in control, and reached 3.94 ± 1.61 in NASH patients compared to 3.20
± 1.22 in simple steatosis. IGF-I; was highly significantly lower in NAFLD patients compared to healthy control participants (58.15
± 20.26 & 130.0 ± 19.44 ng/ml respectively), and was higher 66.81 ± 21.56 ng/ml in non-NASH compared to NASH patients 56.92
± 19.80 ng/ml. eGFR was highly significantly lower in NAFLD patients 60.68 ± 10.17ml/min compared to healthy control 95.81 ±

Salman, Ahmed, Mona Hegazy, and Soheir AbdElfadl. "Combined Adiponectin Deficiency and Resistance in Obese Patients: Can It Solve Part of the Puzzle in Nonalcoholic Steatohepatitis." Open access Macedonian journal of medical sciences 3, no. 2 (2015): 298-302. Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent cause of liver disease, nonalcoholic steatohepatitis (NASH) and fibrosis in obese patients identifies the risk group with increased incidence of liver-related deaths.

AIM: To clarify the role of serum adiponectin and its receptor liver gene expression in the progression of liver damage in NAFLD.

METHODS: Fifty four (54) obese patients with NAFLD preliminary diagnosed by liver ultra-sound were recruited. Full medical history, anthropometric measurement, biochemical studies, serum adiponectin level, liver biopsy for histological examination and NAS score to identify NASH patients, and assessment of adiponectin receptor gene expression by RT-PCR, were conducted for each patients. Fifteen ages matched average weight healthy adult had been chosen as a control for serum adiponectin level.

RESULTS: According to NAS score, patients were divided into non- NASH (8 patients), and NASH (46 patients). Serum adiponectin level was significantly lower in NAFLD patients compared to normal participants (p < 0.004). Serum adiponectin level was lower in NASH patients (4.437 ± 2.569 ng/dl in NASH vs. 5.138 ± 2.841 ng/dl in non-NASH). Adiponectin receptor liver gene expression was lower in NASH patients (0.8459 ± 0.4671 vs. 1.0688 ± 0.3965 in non-NASH).

CONCLUSION: Both adiponectin deficiency and resistance had a role in progression of simple liver steatosis to severe injury in obese patients.

Tawfik, Nehad M., Mona A. Hegazy, Ehab A. Hassan, Yomna K. Ramadan, and Aml S. Nasr. "Egyptian experience of reliability of 4T's score in diagnosis of heparin induced thrombocytopenia syndrome." Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 22, no. 8 (2011): 701-5. Abstract

To evaluate the utility of the 4Ts clinical scoring system as a pretest probability method for detection of heparin-induced thrombocytopenia (HIT). Medical and surgical inpatients and outpatients at Kasr El Eini hospital. This single-centre series of 50 HIT testing referrals assessed combination of clinical score (thrombocytopenia, timing, thrombosis, other causes of thrombocytopenia not evident; 4T's), Heparin platelet factor 4 (H-PF4) rapid particle gel immunoassay (PaGIA) and 14C serotonin release assay (SRA) to develop a practical and well tolerated diagnostic strategy for HIT. Sixteen patients (32%) had a low 4T's score, 26 (52%) had an intermediate score and only eight (16%) had a high score. A positive H-PF4 by PaGIA was seen in seven patients (14%). As might be anticipated, the likelihood of obtaining a positive H-PF4 by PaGIA increased with an increasing clinical score, with positive H-PF4 by PaGIA results in low, intermediate and high scoring patients of 6.25, 7.7 and 50%, respectively. The positive predictive value of a positive PaGIA was 92%. The negative predictive value was 100%. Five patients (10%) in our cohort had a positive SRA. All patients with a positive SRA were included in the intermediate (two of 26 patients, 7.7%) or high (three of eight patients, 37.5%) score groups. The negative predictive value of a low 4T's score was 100%, effectively ruling out HIT. A low 4Ts score supports low probability of HIT based on the results of the PaGIA and SRA. Overall, the interrater reliability of the scoring system was fair.